Nexera <4565> has significantly continued to rise. They have announced the achievement of an important milestone in the research stage of a drug discovery partnership with AbbVie for multiple targets in neurology. As a result, they will receive $10 million, with the majority recognized as revenue in 24 and the remainder in 25 years. Having achieved the first milestone in drug discovery partnership, it seems that further progress in the project can be expected in the future.
ネクセラ---大幅続伸、アッヴィ社との創薬提携においてマイルストンを受領
Nexela---significantly extended, received milestones in drug discovery collaboration with AbbVie.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.